What is Biotricity Inc's earnings per share (EPS)?

Biotricity Inc (BTCY) reported diluted earnings per share of -$0.12 for fiscal year 2026. This represents a 79.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Biotricity Inc Financials

BTCY

Trailing 12 months to June 30, 2026

Revenue $16.4M +13.4% YoY

Net Income -$2.7M +50.1% YoY

EPS (Diluted) -$0.13 +37.6% YoY

Free Cash Flow Not reported for the trailing 12 months

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Jun 30, 2026 Reported Aug 19, 2026 Currency USD FYE March

Biotricity Inc (BTCY) reported $16.4M in revenue over the twelve months to Jun 30, 2026, up 13.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BTCY FY2026 2026-08-15

Operating break-even has emerged through margin expansion and leaner costs, while interest and liabilities still absorb much of the benefit.

The business reached positive operating income of $1.7M in FY2026, yet reported a net loss of -$2.4M; interest expense exceeded operating income. That gap means the core operating model has improved faster than the financing structure: operating profitability exists, but it is not yet reaching the bottom line.

Gross margin widened from 59.7% in FY2022 to 80.9% in FY2026, pointing to improved cost-of-revenue economics or revenue mix rather than growth alone. SG&A fell from $18.6M to $8.5M over the same span, allowing more gross profit to cover the operating base and supporting the move into positive operating income.

Liquidity is the sharper balance-sheet constraint: the latest current ratio was 0.2x, meaning current assets covered only a small fraction of current obligations. Cash was $150K against $41.1M of total liabilities, leaving little cash buffer even as operating cash flow moved closer to break-even.

Financial Health Signals

Financial health score not available

Biotricity Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-33.40

Biotricity Inc scores -33.40, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($2.4M) relative to total liabilities ($41.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

5/8

Biotricity Inc passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Biotricity Inc reported a net loss of $2.4M while operations used $719K of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

0.50x

Biotricity Inc earns $0.50 in operating income for every $1 of interest expense ($1.7M vs $3.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$16.0M

YoY+16.0%

5Y CAGR+36.4%

Biotricity Inc generated $16.0M in revenue in fiscal year 2026. This represents an increase of 16.0% from the prior year.

EBITDA

$1.7M

YoY+169.5%

Biotricity Inc's EBITDA was $1.7M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 169.5% from the prior year.

Net Income

-$2.4M

YoY+71.5%

Biotricity Inc reported -$2.4M in net income in fiscal year 2026. This represents an increase of 71.5% from the prior year.

EPS (Diluted)

-$0.12

YoY+79.3%

Biotricity Inc earned -$0.12 per diluted share (EPS) in fiscal year 2026. This represents an increase of 79.3% from the prior year.

Cash & Balance Sheet

Cash & Debt

$150K

YoY-59.0%

5Y CAGR-41.6%

10Y CAGR-9.6%

Biotricity Inc held $150K in cash as of fiscal year 2026; long-term debt is not reported for that period.

Shares Outstanding

20M

YoY-24.4%

Biotricity Inc had 20M shares outstanding in fiscal year 2026. This represents a decrease of 24.4% from the prior year.

Free Cash Flow

Not reported for fiscal year 2026.

Dividends Per Share

Not reported for fiscal year 2026.

Margins & Returns

Gross Margin

80.9%

YoY+4.3pp

5Y CAGR+43.3pp

Biotricity Inc's gross margin was 80.9% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is up 4.3 percentage points from the prior year.

Operating Margin

10.6%

YoY+28.3pp

Biotricity Inc's operating margin was 10.6% in fiscal year 2026, reflecting core business profitability. This is up 28.3 percentage points from the prior year.

Net Margin

-15.0%

YoY+46.0pp

Biotricity Inc's net profit margin was -15.0% in fiscal year 2026, showing the share of revenue converted to profit. This is up 46.0 percentage points from the prior year.

Return on Equity

Not reported for fiscal year 2026.

Capital Allocation

R&D Spending

$2.8M

YoY+28.2%

5Y CAGR+6.1%

Biotricity Inc invested $2.8M in research and development in fiscal year 2026. This represents an increase of 28.2% from the prior year.

Share Buybacks

Not reported for fiscal year 2026.

Capital Expenditures

Not reported for fiscal year 2026.

BTCY Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BTCY quarterly income statement

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY16	FY15	FY14
Revenue	$16.4M	$16.0M+16.0%	$13.8M+14.3%	$12.1M+25.2%	$9.6M+26.0%	$7.7M+126.0%	$3.4M+138.7%	$1.4M+256.0%	$398K	N/A	N/A	N/A	N/A
Cost of Revenue	$3.0M	$3.0M-5.5%	$3.2M-13.0%	$3.7M-11.7%	$4.2M+36.3%	$3.1M+45.8%	$2.1M+126.6%	$932K+175.5%	$338K	N/A	N/A	N/A	N/A
Gross Profit	$13.4M	$12.9M+22.6%	$10.6M+26.4%	$8.4M+53.6%	$5.4M+19.1%	$4.6M+259.1%	$1.3M+162.0%	$486K+711.4%	$60K	N/A	N/A	N/A	N/A
R&D Expenses	$2.7M	$2.8M+28.2%	$2.2M-16.2%	$2.6M-20.4%	$3.2M+17.7%	$2.7M+33.3%	$2.1M+51.0%	$1.4M+4.1%	$1.3M-25.7%	$1.8M	N/A	$1.1M+37.3%	$833K
SG&A Expenses	$9.1M	$8.5M-21.8%	$10.9M-25.7%	$14.6M-17.1%	$17.6M-5.1%	$18.6M+47.7%	$12.6M	N/A	N/A	N/A	N/A	N/A	$874K
Operating Income	$1.6M	$1.7M+169.1%	-$2.4M+72.3%	-$8.8M+42.7%	-$15.4M+7.9%	-$16.7M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$3.4M	$3.4M+3.1%	$3.3M+8.1%	$3.0M+64.1%	$1.8M+43.3%	$1.3M+745.6%	$152K	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.7M	-$2.4M+71.5%	-$8.4M+40.3%	-$14.1M+24.5%	-$18.7M+35.9%	-$29.1M-88.0%	-$15.5M	N/A	N/A	N/A	N/A	N/A	-$1.7M
EPS (Diluted)	-$0.13	-$0.12+79.3%	-$0.56	-$1.66	-$2.26	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'27	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25
Revenue	$4.3M+0.6%	$4.3M+6.6%	$4.0M+2.6%	$3.9M+0.3%	$3.9M+4.6%	$3.7M+2.3%	$3.6M+10.8%	$3.3M
Cost of Revenue	$746K-12.4%	$852K+15.7%	$736K+4.6%	$704K-7.0%	$757K+4.5%	$724K-15.3%	$855K+5.9%	$808K
Gross Profit	$3.5M+3.9%	$3.4M+4.5%	$3.3M+2.2%	$3.2M+2.1%	$3.1M+4.7%	$3.0M+7.8%	$2.8M+12.4%	$2.5M
R&D Expenses	$673K-20.0%	$842K+35.0%	$624K+3.4%	$603K-13.4%	$696K+21.6%	$573K+3.9%	$551K+6.4%	$518K
SG&A Expenses	$2.7M+44.9%	$1.9M-14.8%	$2.2M-5.1%	$2.3M+7.8%	$2.1M-34.4%	$3.3M+36.9%	$2.4M+5.9%	$2.2M
Operating Income	$158K-77.2%	$695K+57.5%	$441K+61.0%	$274K-2.9%	$282K+133.0%	-$855K-406.2%	-$169K+45.1%	-$308K
Interest Expense	$852K+1.3%	$841K+3.8%	$810K-5.8%	$860K+1.2%	$850K-4.7%	$892K+5.0%	$850K+13.0%	$752K
Net Income	-$959K-196.0%	-$324K+54.8%	-$717K-3.8%	-$691K-2.8%	-$672K+65.3%	-$1.9M-57.5%	-$1.2M+21.3%	-$1.6M
EPS (Diluted)	-$0.05-187.5%	-$0.02+61.9%	-$0.04-44.8%	-$0.030.0%	-$0.03+49.1%	-$0.06-5.6%	-$0.05+26.0%	-$0.07

Not reported in any period shown, so not listed: Income Tax.

BTCY Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BTCY quarterly balance sheet

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY16	FY15	FY14
Total Assets	$6.4M+14.3%	$5.6M-5.1%	$5.9M-8.7%	$6.5M-61.0%	$16.7M+275.8%	$4.4M+121.4%	$2.0M+308.5%	$491K-47.2%	$929K	$68K-87.0%	$519K-0.2%	$520K
Current Assets	$5.9M+26.2%	$4.6M+3.8%	$4.5M-5.3%	$4.7M-69.2%	$15.3M+254.6%	$4.3M+160.5%	$1.7M+262.5%	$458K-48.9%	$896K	$35K-92.9%	$486K-6.5%	$520K
Cash & Equivalents	$150K-59.0%	$365K-53.5%	$786K+37.8%	$570K-95.3%	$12.1M+448.1%	$2.2M+131.8%	$950K+1392.4%	$64K-92.5%	$844K	$21K-95.0%	$411K-8.5%	$449K
Inventory	$1.3M-13.8%	$1.6M-17.2%	$1.9M-19.6%	$2.3M+177.2%	$843K+209.3%	$272K+217.9%	$86K+248.4%	$25K	N/A	N/A	N/A	N/A
Accounts Receivable	$2.9M+76.8%	$1.7M+12.9%	$1.5M+20.0%	$1.2M-39.0%	$2.0M+31.9%	$1.5M+212.8%	$486K+133.6%	$208K	N/A	N/A	N/A	N/A
Total Liabilities	$41.1M+9.2%	$37.7M+0.7%	$37.4M+41.9%	$26.4M+40.0%	$18.8M+67.0%	$11.3M+125.2%	$5.0M+120.6%	$2.3M+200.0%	$756K	$4.1M+135.2%	$1.8M+898.8%	$176K
Current Liabilities	$37.1M+80.0%	$20.6M-9.1%	$22.7M+103.4%	$11.2M+129.3%	$4.9M-53.6%	$10.5M+175.8%	$3.8M+67.7%	$2.3M	N/A	N/A	$413K+134.8%	$176K
Total Equity	-$34.7M-8.3%	-$32.0M-1.7%	-$31.5M-58.6%	-$19.8M-825.3%	-$2.1M+68.6%	-$6.8M-127.7%	-$3.0M-68.8%	-$1.8M-1126.1%	$173K	-$4.1M-228.3%	-$1.2M-460.3%	$344K
Retained Earnings	-$142.6M-2.2%	-$139.4M-9.4%	-$127.5M-13.3%	-$112.6M-21.0%	-$93.0M-48.1%	-$62.8M-35.5%	-$46.4M-32.3%	-$35.0M-32.5%	-$26.4M	-$16.5M-78.9%	-$9.2M-128.3%	-$4.0M

Metric	Q1'27	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25
Total Assets	$6.0M-6.6%	$6.4M+13.4%	$5.7M-10.1%	$6.3M+4.7%	$6.0M+7.0%	$5.6M-5.8%	$6.0M+13.1%	$5.3M
Current Assets	$5.6M-4.4%	$5.9M+17.6%	$5.0M-10.0%	$5.5M+7.6%	$5.1M+10.9%	$4.6M-4.6%	$4.9M+19.6%	$4.1M
Cash & Equivalents	$467K+211.4%	$150K-41.6%	$256K-16.9%	$308K-21.2%	$391K+7.2%	$365K-28.3%	$510K+194.1%	$173K
Inventory	$1.4M+6.2%	$1.3M-32.1%	$2.0M-12.5%	$2.3M+26.5%	$1.8M+14.7%	$1.6M-0.9%	$1.6M-13.6%	$1.8M
Accounts Receivable	$2.4M-18.2%	$2.9M+85.8%	$1.6M-24.8%	$2.1M+12.8%	$1.9M+12.2%	$1.7M+34.2%	$1.2M-17.6%	$1.5M
Total Liabilities	$41.4M+0.7%	$41.1M+3.0%	$39.9M+0.5%	$39.7M+2.3%	$38.8M+3.1%	$37.7M-0.7%	$37.9M+4.0%	$36.5M
Current Liabilities	$37.3M+0.5%	$37.1M+56.1%	$23.8M+0.8%	$23.6M+8.3%	$21.8M+5.7%	$20.6M-2.4%	$21.1M-1.6%	$21.5M
Total Equity	-$35.4M-2.1%	-$34.7M-1.3%	-$34.2M-2.5%	-$33.4M-1.9%	-$32.8M-2.5%	-$32.0M-0.2%	-$31.9M-2.5%	-$31.2M
Retained Earnings	-$143.6M-0.8%	-$142.6M-0.3%	-$142.1M-0.8%	-$141.0M-0.6%	-$140.2M-0.5%	-$139.4M-1.5%	-$137.4M+1.5%	-$139.4M

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

BTCY Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BTCY quarterly cash flow statement

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY16	FY15	FY14
Operating Cash Flow	$162K	-$719K+69.8%	-$2.4M+64.4%	-$6.7M+50.6%	-$13.5M+10.7%	-$15.2M-36.8%	-$11.1M-40.9%	-$7.9M	N/A	N/A	N/A	-$2.0M-42.1%	-$1.4M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$30K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	-$15.2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	-$30K	N/A	N/A	N/A	N/A	N/A	$0	$0
Financing Cash Flow	-$69K	$558K-71.1%	$1.9M-71.4%	$6.7M+236.8%	$2.0M-92.0%	$25.2M+106.2%	$12.2M+37.4%	$8.9M	N/A	N/A	N/A	$2.0M+16.4%	$1.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	$603K+235.0%	$180K	N/A	N/A	N/A	N/A	N/A

Metric	Q1'27	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25
Operating Cash Flow	$507K+2526.3%	-$21K+97.2%	-$740K-278.1%	$416K+211.3%	-$373K+6.8%	-$401K-355.0%	-$88K+77.8%	-$397K
Financing Cash Flow	-$191K-108.6%	-$92K-112.7%	$721K+242.1%	-$508K-216.5%	$436K+164.0%	$165K-61.2%	$425K-9.8%	$471K

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

BTCY Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

BTCY quarterly financial ratios

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY16	FY15	FY14
Gross Margin	80.9%+4.3pp	76.6%+7.3pp	69.3%+12.8pp	56.5%-3.3pp	59.7%+22.1pp	37.6%+3.3pp	34.3%+19.2pp	15.0%	N/A	N/A	N/A	N/A
Operating Margin	10.6%+28.3pp	-17.8%+55.4pp	-73.2%	-159.9%	-218.8%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-15.0%+46.0pp	-61.1%	-116.8%	-193.6%	-380.8%	-457.7%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-496.1%
Return on Assets	-37.3%+112.0pp	-149.3%+87.9pp	-237.2%+49.4pp	-286.6%-111.9pp	-174.7%+174.4pp	-349.1%	N/A	N/A	N/A	N/A	N/A	-328.2%
Current Ratio	0.16-0.1x	0.220.0x	0.20-0.2x	0.42-2.7x	3.15+2.7x	0.410.0x	0.44+0.2x	0.20	N/A	N/A	1.18-1.8x	2.95
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	4.36	N/A	N/A	0.51
FCF Margin	N/A	N/A	N/A	N/A	-198.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'27	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25
Gross Margin	82.5%+2.6pp	80.0%-1.6pp	81.5%-0.3pp	81.9%+1.4pp	80.5%0.0pp	80.4%+4.1pp	76.4%+1.1pp	75.3%
Operating Margin	3.7%-12.6pp	16.3%+5.3pp	11.1%+4.0pp	7.0%-0.2pp	7.3%+30.4pp	-23.1%-18.4pp	-4.7%+4.8pp	-9.4%
Net Margin	-22.4%-14.8pp	-7.6%+10.3pp	-18.0%-0.2pp	-17.8%-0.4pp	-17.3%+34.9pp	-52.3%-18.3pp	-34.0%+13.9pp	-47.8%
Return on Assets	-15.9%-10.9pp	-5.0%+7.6pp	-12.6%-1.7pp	-10.9%+0.2pp	-11.1%+23.2pp	-34.3%-13.8pp	-20.5%+9.0pp	-29.5%
Current Ratio	0.150.0x	0.16-0.1x	0.210.0x	0.230.0x	0.240.0x	0.220.0x	0.230.0x	0.19

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, FCF Margin.

Note: Shareholder equity is negative (-$34.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.16), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Guided Thera GTHP

$20.3M

CS Diagnostics CSDX

$2.6M

Perimeter Medical Imaging Ai Inc PYNKF

$27.1M

PharmChem, Inc. PCHM

$17.3M

Petvivo Hldgs Inc PETV

$22.8M

Where Biotricity Inc Ranks

Frequently Asked Questions

What is Biotricity Inc's annual revenue?

Biotricity Inc (BTCY) reported $16.0M in total revenue for fiscal year 2026. This represents a 16.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Biotricity Inc's revenue growing?

Biotricity Inc (BTCY) revenue grew by 16.0% year-over-year, from $13.8M to $16.0M in fiscal year 2026.

Is Biotricity Inc profitable?

No, Biotricity Inc (BTCY) reported a net income of -$2.4M in fiscal year 2026, with a net profit margin of -15.0%.

What is Biotricity Inc's EBITDA?

Biotricity Inc (BTCY) had EBITDA of $1.7M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is Biotricity Inc's gross margin?

Biotricity Inc (BTCY) had a gross margin of 80.9% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is Biotricity Inc's operating margin?

Biotricity Inc (BTCY) had an operating margin of 10.6% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is Biotricity Inc's net profit margin?

Biotricity Inc (BTCY) had a net profit margin of -15.0% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

What is Biotricity Inc's operating cash flow?

Biotricity Inc (BTCY) recorded an outflow of $719K in operating cash flow during fiscal year 2026, representing cash used by core business activities.

What are Biotricity Inc's total assets?

Biotricity Inc (BTCY) had $6.4M in total assets as of fiscal year 2026, including both current and long-term assets.

How much does Biotricity Inc spend on research and development?

Biotricity Inc (BTCY) invested $2.8M in research and development during fiscal year 2026.

How many shares does Biotricity Inc have outstanding?

Biotricity Inc (BTCY) had 20M shares outstanding as of fiscal year 2026.

What is Biotricity Inc's current ratio?

Biotricity Inc (BTCY) had a current ratio of 0.16 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.

What is Biotricity Inc's return on assets (ROA)?

Biotricity Inc (BTCY) had a return on assets of -37.3% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

How does Biotricity Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2026, Biotricity Inc (BTCY) held $150K in cash, cash equivalents and investments, and reported an operating cash outflow of $719K over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is Biotricity Inc's debt-to-equity ratio negative or not reported?

Biotricity Inc (BTCY) has negative shareholder equity of -$34.7M as of fiscal year 2026, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Biotricity Inc's Altman Z-Score?

Biotricity Inc (BTCY) has an Altman Z-Score of -33.40, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Biotricity Inc's Piotroski F-Score?

Biotricity Inc (BTCY) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Biotricity Inc's earnings high quality?

Biotricity Inc (BTCY) reported a net loss of $2.4M while operations used $719K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Biotricity Inc cover its interest payments?

Biotricity Inc (BTCY) has an interest coverage ratio of 0.50x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.